Skip to main content

Pharma News

Pharma Courses

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • Weight loss and blood glucose are early indicators of pancreatic cancer

    Pancreatic cancer could be identified in patients up to three years earlier than current diagnoses, new research suggests. Weight loss and increasing blood glucose levels are early indicators of pancreatic cancer and could lead to a more timely diagnosis, helping to improve survival rates.

  • mRNA COVID vaccine elevates cardiovascular risk, finds study

    A comprehensive review and meta-analysis of published research confirm that young adults (40 years old and younger) have a slightly elevated risk for myocarditis or pericarditis after mRNA COVID-19 vaccination. The analysis is reported in a new study in the American Journal of Preventive Medicine, published by Elsevier.

  • Alembic receives approval from the USFDA for Mesalamine ER Capsules

    Alembic Pharmaceuticals Limited (Alembic) announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Mesalamine Extended-Release Capsules USP, 0.375 g.

    The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Apriso Extended-Release Capsules, 0.375 g, of Salix Pharmaceuticals, Inc. (Salix).

  • Sun Pharma shows 13 percent growth for Q2

    Sun Pharma records growth of 13.1 percent over Q2 last year.  The gross sales reached at Rs. 108,092 million. In this quarter, the company launched 34 new products in the Indian market.

    Sun Pharma market share has increased by 0.5 pc to 8.6 pc over the last one year, as per AIOCD AWACS MAT Sept-2022 report. As per SMSRC MAT August-2022 report, Sun Pharma is topped in prescriptions with 12 different doctor categories.

  • Glenmark Pharmaceuticals launches Fingolimod Capsules in the US

    Glenmark Pharmaceuticals Inc., USA (Glenmark) is pleased to announce it has launched their Fingolimod Capsules, 0.5 mg, the generic version of Gilenya®1 Capsules, 0.5 mg, of Novartis Pharmaceuticals Corporation.

    Commenting on the launch, Sanjeev Krishan, President, Glenmark North America said, “We are very pleased to bring to market a lower cost alternative to Gilenya® Capsules, 0.5 mg. This launch confirms our commitment to provide quality and affordable pharmaceutical products to patients.”

  • The origin-of-life molecule, a key to cancer research

    A study by researchers at the Biomedical Institute of Seville (IBIS) and the University of Seville, in collaboration with the Danish Cancer Society, revealed that inhibiting RNA synthesis after radiation therapy facilitates the death of tumour cells. The study has been published in the prestigious journal Nature Communications.

  • Antioxidant benefits of honey explored

    Citrus honey has an increased abundance of antioxidants in comparison to other standard types of honey, according to a new study by University of the West of Scotland (UWS).

    Antioxidants are chemicals that reduce or prevent the effects of free radicals: unstable molecules that can damage cells, causing illness, disease, and ageing.

  • Study overcomes the obstacles to treatment for colon cancer

    Colorectal cancer is one of the most common cancers. Its treatment is mainly based on chemotherapy. However, over time, chemotherapy induces resistance in the majority of patients, who end up being unresponsive to the drugs. As a result, the five-year survival rate for those affected is still low. After succeeding in reproducing this resistance in the laboratory, a team from the University of Geneva (UNIGE) has found a way to overcome it.

  • PCI mandates to implement PPR 2015

    The Pharmacy Council of India (PCI) has directed all the State and Union Territory (UT) governments and State Pharmacy Council to immediately implement the Pharmacy Practice Regulations (PPR), 2015. In January 2015, PCI had already notified about the implementation of the PPR,2015.

  • USFDA Grants Emergency Use Authorization for Novavax COVID-19 Vaccine

    Novavax, Inc a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the Novavax COVID-19 Vaccine, Adjuvanted (NVX-CoV2373) has received emergency use authorization (EUA) from the U.S.

Subscribe to Pharma News